The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract

International Journal of Gynecological Cancer

Volumn 4, Issue 1, 1994, Pages 52-60

  Van Rijswijk, R E N ^a   Tognon, G ^a   Burger, C W ^a   Baak, J P ^a   Kenemans, P ^a   Vermorken, J B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CA 125; Carcinosarcoma; Chemotherapy; Malignant mixed mesodermal tumor; Review

Indexed keywords

BLEOMYCIN; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL ARTICLE; DISEASE COURSE; DRUG FEVER; FEMALE; FEMALE GENITAL SYSTEM; GENITAL TRACT TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; NEUROTOXICITY; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0028011953     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1994.04010052.x     Document Type: Article

References (52)

1. Solis OG, Bui HX, Malfetano JH, Ross JS. Extragenital primary mixed malignant mesodermal tumor. Gynecol Oncol 1991; 43: 182-85.
2. Garde JR, Jones MA, McAfee R, Tarraza HM. Extragenital malignant mixed Millerian tumor: review of the literature. Gynecol Oncol 1991; 43: 186-90.
3. Muntz HG, Rutgers J, Tarraza HM, Fuller AF. Carcinosarcomas and mixed Mllarian tumors of the fallopian tube. Gynecol Oncol 1989; 34: 109-15.
4. Nielsen SN, Podratz KC, Scheithauer BW, CYBrien PC. Clinicopathologic analysis of uterine malignant mixed Mifllarian tumors. Gynecol Oncol 1989; 34: 372-78.
5. George M, Pejovic MH, Kramar A. Uterine sarcomas: prognostic factors and treatment modalities - study on 209 patients. Gynecol Oncol 1986; 24: 58-67.
6. Podczaski ES, Woomert CA, Stevens CW Jr, et al. Management of malignant mixed mesodermal tumors of the uterus. Gynecol Oncol 1989; 32: 240-44.
7. Hanjani P, Petersen RO, Lipton SE, Nolte SA. Malignant mixed mesodermal tumors and carcinosarcomas of the ovary: report of 8 cases and review of the literature. Obstet Gynecol Surv 1983; 38: 537--45.
8. Suggs CL HI, Lee JL Jr, Choi H, Lewis GC. Malignant mixed mesodermal tumors of the ovary. A report of 13 cases. Am J Clin Oncol 1988; 11: 12-15.
9. Plaxe SC, Dottino PR, Goodman HM, Deligdisch L, Idelson M, Cohen CJ. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy. Gynecol Oncol 1990; 37: 244-49.
10. Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 1989; 32: 228-32.
11. Andersen WA, Young DE, Peters WA III, Smith EB, Bagley CM, Taylor PT Jr. Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 1989; 32: 319-22.
12. Baker TR, Piver MS, Caglar H, Piedmonte M. Prospective trial of cisplatin adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991; 14: 246-50.
13. Salazar OM, Bonfiglio TA, Patten SF, et al. Uterine sarcomas. Natural history, treatment and prognosis. Cancer 1978, 42: 1152-60.
14. Spanos WJ, Peters LJ, Oswald MJ. Patterns of recurrence in malignant mixed mesodermal Miillarian tumor of the uterus. Cancer 1986; 57: 155-59.
15. Salazar OM, Bonfiglio TA, Patten SF, et al. Uterine sarcomas. Analysis of failures with special emphasis on the use of adjuvant radiotherapy. Cancer 1978; 42: 1161-70.
16. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985; 9: 1240-45.
17. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626-32.
18. Morrow CP, Bundy BN, Hoffman J, Sutton G, Homesley H. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A Gynecologic Oncology Group Study. Am J Clin Oncol 1986; 9: 24-26.
19. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Freedman RS, Wharton JT. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 1987; 59: 1264-67.
20. Muss HB, Bundy B, Disaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase m trial of the Gynecologic Oncology Group). Cancer 1985; 55: 1648-53.
21. Thigpen JT, Blessing JA, Orr JW Jr, DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 1986; 70: 271-74.
22. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Stringer CA, Wharton JT. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987; 5: 618-21.
23. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1991; 9: 1962-66.
24. Seltzer V, Kaplan B, Vogl S, Spitzer M. Doxorubicin and cisplatin in the treatment of advanced mixed mesodermal uterine sarcoma. Cancer Treat Rep 1984; 58: 1389-90.
25. Peters WA III, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol 1989; 34: 323-27.
26. Grosh WW, Jones HW III, Burnett LS, Greco FA. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy. Gynecol Oncol 1986; 25: 334-39.
27. Moore M, Pine S. Malignant mesodermal tumors of the ovary: the Princess Margaret Hospital experience. Proc ASCO 1986; 5: 114.
28. Wheelock J, Hancock K, Smith K. Cisplatin, doxorubicin, and cydophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary. Cancer Treat Rep 1987; 71: 1275-76.
29. Jansen RL, van der Burg ME, Verweij J, Stoter G. Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract. Eur J Cancer Clin Oncol 1987; 23: 1131-33.
30. Malviya V, Deppe G, Malone J. Cis-platinum based combination chemotherapy in advanced metastatic mixed mesodermal sarcoma of the uterus. Proc ASCO 1988; 7: 142.
31. Piver S, Lele SB, Patsner B. cis-Diamminedichloroplatinum plus dimethyl-triazenoimidazole carboxamide as secondand third-line chemotherapy for sarcomas of the female pelvis. Gynecol Oncol 1986; 23; 371-75.
32. Lele SB, Piver MS, Barlow JJ. Chemotherapy in management of mixed mesodermal tumors of the ovary. Gynecol Oncol 1980; 10: 298-302.
33. Piver MS, DeEulis TG, Lele SB, Baflow J. Cydophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol 1982; 14: 319-23.
34. Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of uterine sarcoma with adriamycin. Gyncecol Oncol 1983; 16: 101-4.
35. Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. A clinical and pathologic study of 30 cases of malignant mixed Mullerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group study. Gynecol Oncol 1984; 18: 278-92.
36. Carlson JA, Edwards C, Wharton JT, GaUager HS, Delclos L, Rutledge F. Mixed mesodermal tumors of the ovary. Treatment with combination radiation therapy and chemotherapy. Cancer 1983; 52: 1473-77.
37. Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol 1983; 15: 224-29.
38. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987; 23: 311-21.
39. Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD. Gynecologic Oncology Group experience with ifosfamide. Semin Oncol 1990; 17: 6-10.
40. Muss HB, Bundy BN, Adcock L, Beecham J. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990; 13: 32-34.
41. Slayton RE, Blessing JA, DiSaia PJ, Christopherson WA. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 1987; 71: 661-662.
42. Meiss JM, Lawrence WD. The immunohistochemical profile of malignant mixed Millarian tumor. Am J Clin Pathol 1990; 94: 1-7.
43. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990; 14: 317-328.
44. Noorduyn LA, Herman CJ. The relation between mixed mesodermal tumors and adenocarcinomas of the ovary. An immunopathologic study. Eur J Cancer Clin Oncol 1987; 23: 157-162.
45. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990; 9: 1-19.
46. Deligdisch L, Plaxe S, Cohen CJ. Extrauterine pelvic malignant mixed mesodermal tumors. A study of 10 cases with immunohistochemistry. Int J Gynecol Pathol 1988; 7: 361-72.
47. Doss LL, Llorens AS, Henriques EM. Carcinosarcoma of the uterus: a 40-year experience from the state of Missouri. Gynecol Oncol 1984; 18: 43-53.
48. Fleming WP, Peters WA III, Kumar NB, Morley GW. Autopsy findings in patients with uterine sarcoma. Gynecol Oncol 1984; 19: 168-72.
49. Patsner B, Mann WJ. Use of serum CA-125 in monitoring patients with uterine sarcoma. Cancer 1988; 62: 1355-58.
50. Peters WA, Bagley CM, Smith MR. CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer 1986; 58: 2625-27.
51. Vergote IB, Bormer OP, Abeler VM. Evaluation of CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987; 157: 88-92.
52. Yedema C, Kenemans P, Voorhorst F, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993 (in press).